Portfolio
Clavis Pharma ASA is a pharmaceutical company creating patented new drug analogs of existing drugs based on its proprietary Lipid Vector Technology.
The new drug analogs offer improved efficacy and safety profile, prolonged effect allowing for more convenient dosing schedule, more convenient administration as well as opening up for new clinical indications.
Clavis Pharma ASA was founded in August 2001 by NeoMed and Norsk Hydro.
In 2006 the company successfully completed an Initial Public Offering on Oslo Stock Exchange (OSE:CLAVIS).
Status: Realised
Investment
NeoMed founded Clavis Pharma ASA in 2001 and played a major role in all aspects of corporate development.
NeoMed led the asset spin out negotiations with Norsk Hydro, acted as CEO, board director and chairman and recruited the first employee.
NeoMed led the Series A financing and attracted international venture capitalists in the Series B.
Finally, NeoMed led the public offering of the company on the Oslo Stock Exchange.
NeoMed realised its stakeholding in 2010 by distributing its remaining shares in kind to investors.